Futibatinib is an orally available pan-FGFR inhibitor that is currently being evaluated in a phase II trial as monotherapy and in combination with fulvestrant in patients with locally advanced or metastatic breast cancer harboring FGFR gene amplification (NCT04024436)
PMC12595317 Badenhorst T, Svirskis D, Merrilees M, et al
If fatigue and muscle aches continue despite home care, it is important to seek professional evaluation
A: Transparent Labs ships Worldwide, except to the following countries, unfortunately, due to increasingly high fraudulent activity
Information about medicinal products published on this website is provided for informational purposes only and does not constitute advertising, a public offer, an offer for sale, or instructions for use
Antioxidant and hydration support